Journal
JOURNAL OF NEURO-ONCOLOGY
Volume 123, Issue 3, Pages 323-330Publisher
SPRINGER
DOI: 10.1007/s11060-015-1810-5
Keywords
Glioblastoma; Glioma; Checkpoint; Vaccine; Immunotherapy
Categories
Funding
- NCI NIH HHS [P30 CA006973] Funding Source: Medline
Ask authors/readers for more resources
Immunotherapy is coming to the fore as a viable anti-cancer treatment modality, even in poorly immunogenic cancers such as glioblastoma (GBM). Accumulating evidence suggests that the central nervous system may not be impervious to tumor-specific immune cells and could be an adequate substrate for immunologic anti-cancer therapies. Recent advances in antigen-specific cancer vaccines and checkpoint blockade in GBM provide promise for future immunotherapy in glioma. As anti-GBM immunotherapeutics enter clinical trials, it is important to understand the interactions, if any, between immune-based treatment modalities and the current standard of care for GBM involving chemoradiation and steroid therapy. Current data suggests that chemoradiation may not preclude the success of immunotherapeutics, as their effects may be synergistic. The future of therapy for GBM lies in the power of combination modalities, involving immunotherapy and the current standard of care.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available